Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.7K Buy
170
+166
+4,150% +$18.8K ﹤0.01% 767
2026
Q1
$445 Buy
+4
New +$473 ﹤0.01% 1756

Other funds holding ABVX

Basecamp Wealth Advisors's ABVX Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Abivax (ABVX) stake by 4,150% in Q2 2026, buying an estimated $18.8K and bringing the position to 170 shares worth $22.7K. The position accounts for ﹤0.01% of the portfolio, ranked #767.

Basecamp Wealth Advisors first reported a position in ABVX in Q1 2026 and has held it in 2 quarters since. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Basecamp Wealth Advisors held 170 shares of Abivax worth $22.7K as of Q2 2026.
  • Basecamp Wealth Advisors bought 166 Abivax shares in Q2 2026, an estimated $18.8K.
  • Abivax made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #767 holding.
  • Basecamp Wealth Advisors first reported a position in Abivax in Q1 2026 and has held it in 2 quarters since.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.